选择性TGF-β配体陷阱可减轻肺动脉高压
该研究在多种实验性肺动脉高压模型中检验选择性TGF-β1/3配体陷阱TGFBRII-Fc的作用。体外显示TGFBRII-Fc抑制TGF-β1和TGF-β3(非TGF-β2)信号;在单野百合碱及SU5416/低氧大鼠和小鼠模型中减轻肺动脉高压与肺血管重构,已建立PH的大鼠中改善右室收缩压、右室功能与生存,未观察到心脏结构或瓣膜异常。
要点
- TGFBRII-Fc选择性阻断TGF-β1/3而非TGF-β2信号
- 多种实验性PH模型中减轻肺动脉高压和肺血管重构
- 已建立PH的动物中改善右室功能与生存且未见瓣膜异常
核心结论
- 选择性TGF-β1/3配体阻断可改善多种实验性PH模型的血流动力学、重构与生存,并具耐受性。
研究设计与样本
- 体外用人肺动脉平滑肌细胞做信号研究;体内在单野百合碱处理Sprague-Dawley大鼠、SU5416/低氧处理Sprague-Dawley大鼠及SU5416/低氧处理C57BL/6小鼠中研究PH。
主要发现
- TGFBRII-Fc抑制TGF-β1和TGF-β3信号,但不抑制TGF-β2信号。
- TGFBRII-Fc减轻Smad2磷酸化、使纤溶酶原激活物抑制剂-1表达正常化,并减轻三种模型的PH与肺血管重构。
- 对已建立PH的单野百合碱或SU5416/低氧大鼠,TGFBRII-Fc改善右室收缩压、右室功能和生存。
- TGFBRII-Fc治疗后未观察到心脏结构或瓣膜异常。
临床怎么用
- 提示选择性TGF-β1/3配体阻断可能成为PH的候选治疗策略,尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Transforming growth factor-β (TGF-β) ligands signal via type I and type II serine-threonine kinase receptors to regulate broad transcriptional programs. Excessive TGF-β-mediated signaling is implicated in the pathogenesis of pulmonary arterial hypertension, based in part on the ability of broad inhibition of activin-like kinase (ALK) receptors 4/5/7 recognizing TGF-β, activin, growth and differentiation factor, and nodal ligands to attenuate experimental pulmonary hypertension (PH). These broad inhibition strategies do not delineate the specific contribution of TGF-β versus a multitude of other ligands, and their translation is limited by cardiovascular and systemic toxicity. OBJECTIVES: We tested the impact of a soluble TGF-β type II receptor extracellular domain expressed as an immunoglobulin-Fc fusion protein (TGFBRII-Fc), serving as a selective TGF-β1/3 ligand trap, in several experimental PH models. METHODS: Signaling studies used cultured human pulmonary artery smooth muscle cells. PH was studied in monocrotaline-treated Sprague-Dawley rats, SU5416/hypoxia-treated Sprague-Dawley rats, and SU5416/hypoxia-treated C57BL/6 mice. PH, cardiac function, vascular remodeling, and valve structure were assessed by ultrasound, invasive hemodynamic measurements, and histomorphometry. MEASUREMENTS AND MAIN RESULTS: TGFBRII-Fc is an inhibitor of TGF-β1 and TGF-β3, but not TGF-β2, signaling. In vivo treatment with TGFBRII-Fc attenuated Smad2 phosphorylation, normalized expression of plasminogen activator inhibitor-1, and mitigated PH and pulmonary vascular remodeling in monocrotaline-treated rats, SU5416/hypoxia-treated rats, and SU5416/hypoxia-treated mice. Administration of TGFBRII-Fc to monocrotaline-treated or SU5416/hypoxia-treated rats with established PH improved right ventricular systolic pressures, right ventricular function, and survival. No cardiac structural or valvular abnormalities were observed after treatment with TGFBRII-Fc. CONCLUSIONS: Our findings are consistent with a pathogenetic role of TGF-β1/3, demonstrating the efficacy and tolerability of selective TGF-β ligand blockade for improving hemodynamics, remodeling, and survival in multiple experimental PH models.
引用
- Yung LM, Nikolic I, Paskin-Flerlage SD, et al. A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension. Am J Respir Crit Care Med. 2016. PMID: 27115515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。